UCHL1 and concussion: So far, the combination of ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) has been approved by the US Food and Drug Administration (FDA) for clinical use in mTBI patients (15).